Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:approvalYear |
2018
2023 |
| gptkbp:approvedBy |
gptkb:nasopharyngeal_carcinoma
gptkb:China gptkb:United_States melanoma |
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:brand |
Tuoyi
|
| gptkbp:CASNumber |
1923910-46-8
|
| gptkbp:developedBy |
gptkb:Coherus_BioSciences
gptkb:Shanghai_Junshi_Biosciences |
| https://www.w3.org/2000/01/rdf-schema#label |
toripalimab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:PD-1
|
| gptkbp:UNII |
6Q1K1Y1K0F
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:programmed_cell_death_protein_1_(PD-1)
|
| gptkbp:bfsLayer |
6
|